A new era for century-old enterprises. Sandoz Pharmaceuticals, the world’s third-largest maker of generics and biosimilars, is embarking on a new phase as it aims to overtake Novartis, the company it is considered to be the origin of its creation, after its spin-off on September 15 Approval. As Joaquín Rodrigo, the company’s Spanish president and general manager of Sandoz Iberia, explained on Tuesday in Madrid, “Our brand, after being established as an independent company and starting to trade, wants to continue to be a brand that promotes patient access Pioneer of Health” was listed on the SIX Swiss Exchange in Zurich on October 4. ” It debuted on the Swiss stock market, within indicators of the country’s 30 largest companies, leading to a rise in the share price, which now has a market capitalization of nearly 11 billion euros.
In Spain, the head of the company has confirmed that the €50 million investment in the Palafolls (Barcelona) plant announced in 2021 will begin immediately and will last until 2025. Likewise, he confirmed that at the end of next year the Sandoz factory in Les Franqueses del Vallés (Barcelona) will be closed due to the technical obsolescence of the facility. Sandoz People and Talent Director Francisco de la Calle explained that 40% of the 260 employees will be relocated to Para Falls, with the remainder already agreed with the company through a social program through pre-retirement and retirement Process resignation. Iberia.
Despite this adjustment, De la Calle highlighted employee headcount growth of more than 43% last year, “a clear commitment to diverse and inclusive talent that has led us to a workforce of over 800 collaborators today.” Facts , the company has seven global centers of excellence offering international services in Madrid, which will add approximately 150 new members to the company’s team.
Both executives emphasized: “These global centers of excellence are clear examples of the company’s commitment to digitalization and the application of new technologies in areas such as safety and environment, data management and artificial intelligence or technology and transformation.”
When asked if the company faces particular difficulties in recruiting the required professionals, Dracalle explained that they have the ability to manage existing in-house talent and denied that they are seeing too many problems attracting new professionals. In fact, he recalled, employee turnover was only 4%, a level he described as excellent.
Its leading product portfolio includes more than 1,500 products that treat conditions ranging from the common cold to cancer. Sandoz is headquartered in Basel, Switzerland, and its history can be traced back to 1886. Its history of progress includes the launch of Sandoz calcium in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2022, Sandoz achieved sales of US$9.1 billion and earned EBITDA of US$1.9 billion.
Follow all information five days exist Facebook, X and LinkedInor in our newsletter five day agenda
five day agenda
Today’s most important economic quotes, along with the keys and context for understanding their scope
receive it